H.C. Wainwright lowered the firm’s price target on Prothena (PRTA) to $14 from $30 and keeps a Buy rating on the shares after the company announced that the AFFIRM-AL trial did not show statistical significance on the survival benefit, the primary endpoint for the study. The firm removed birtamimab from the current valuation but says PRX012 remains on track.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA: